Arthurian Life Sciences

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Rutherford Health Plc is a provider of cancer care services in the United Kingdom, operating a network of oncology centers known as Rutherford Cancer Centres. The company offers a comprehensive range of treatments, including proton beam therapy, radiotherapy, chemotherapy, immunotherapy, and various diagnostic services such as computerized tomography and magnetic resonance imaging. It caters to private patients with medical insurance, self-pay patients, and individuals referred by the National Health Service. Founded in 2015 and based in Hereford, Rutherford Health also engages in development and infrastructure activities to enhance its service offerings. The company has established a strategic collaboration with Panthera Biopartners to further advance its capabilities in cancer treatment.

Apitope is a biotechnology company dedicated to the discovery and development of disease-modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves' disease, and uveitis. The company specializes in creating antigen-specific therapeutic peptides that directly target the underlying causes of these conditions. Apitope's innovative approach aims to provide effective treatments that enhance patients' quality of life while minimizing the risk of secondary infections and complications. The company's first product candidate is licensed to Merck Serono, and it continues to advance its remaining portfolio of product candidates developed through its proprietary platform technology.

CeQur Simplicity focuses on improving the lives of individuals with diabetes by creating innovative drug-delivery devices. The company has developed a discreet and wearable insulin delivery device that simplifies the administration of both basal and bolus insulin for up to three days. This technology enables patients to effectively engage in intensive insulin therapy without the daily inconvenience of injections. By collaborating with healthcare professionals and diabetes centers, CeQur Simplicity aims to enhance patient care and accessibility to its user-friendly insulin delivery solutions.

Sphere Medical Holding is a company based in the United Kingdom that develops and manufactures medical monitoring and diagnostic equipment for critical care environments. Founded in 2001, the company specializes in creating innovative monitoring products that enable healthcare professionals to measure blood gases, electrolytes, and metabolites, which are essential for managing therapy for ill and unstable patients. Its flagship Proxima solution is designed to provide real-time data on various clinical analytes, including pH, glucose, and electrolytes, facilitating faster clinical decision-making and optimizing patient outcomes. In addition to analyzers for intensive care units and operating rooms, Sphere Medical offers cardiopulmonary bypass monitors and specialized sensors for catheters and other measurement probes. The company's commitment to research and development ensures that its products remain at the forefront of medical technology.

Interrad Medical is a medical device company located in Plymouth, Minnesota. The company was founded by Dr. Michael Rosenberg, a practicing interventional radiologist, in collaboration with several other highly regarded physicians. The company's mission is the development and commercialization of innovative medical devices for use in minimally invasive interventional and surgical procedures. Interrad Medical has an experienced market-proven team with a successful track record of bringing devices through development to commercialization. it has a robust product portfolio targeting minimally invasive vascular and surgical procedures. These devices are designed to solve unmet medical needs and serve large, growing patient populations.

MedaPhor Limited, an e-learning company, produces training products for postgraduate medical professionals. The company offers tutorials for learning or improving ultrasound examination techniques; and simulation technology solutions for medical education and training. Its solutions include Blue Phantom, which offers ultrasound phantoms for hands-on gynaecological and obstetrics simulation training; True Anatomy, an endovaginal training model for ultrasound simulation training; and intrauterine pregnancy, ectopic pregnancy, and general pathology models. The company was incorporated in 2004 and is based in Cardiff, the United Kingdom.

ReNeuron Group is a biotechnology company based in Pencoed, United Kingdom, specializing in the research, development, and commercialization of cell-based therapies. The company is advancing its CTX stem cell therapy, which is currently in Phase IIb clinical trials aimed at addressing stroke-related disabilities. Additionally, it is developing human retinal progenitor cell therapy, which is in Phase I/IIa trials for treating retinitis pigmentosa, a condition that can lead to blindness. ReNeuron is also exploring CTX-derived exosomes, which are nano-sized packages that contain information from CTX cells. The company holds a research agreement with a U.S. biotechnology firm to develop innovative therapeutics based on gene silencing. Founded in 1997, ReNeuron Group generates revenue from its activities in both the UK and the U.S., focusing on conditions such as stroke disabilities, inherited retinal diseases, and cancer.